Pulmonary Resection for Metastases from Hepatocellular Carcinoma

Chen, Fengshi; Satô, Kiyoshi; Fujinaga, Takuji; Sonobe, Makoto; Tanaka, Shōji; Sakai, Hiroaki; Miyahara, Ryoji; Bando, Toru; Okubo, Kan; Hirata, Toshiki; Date, Hiroshi

doi:10.1007/s00268-008-9684-8

Cited by 38 publications

(32 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Hepatectomies carried out in the same period that were considered non-curative because gross tumour remained after operation were not included in this study. Patients who had resectable extrahepatic recurrence were also excluded as it was presumed that they would have different disease characteristics 7,20 .…”

Section: Methodsmentioning

confidence: 99%

Second and third hepatectomies for recurrent hepatocellular carcinoma are justified

Cheng

Yeh

et al. 2009

British Journal of Surgery

View full text Add to dashboard Cite

show abstract

Section: Methodsmentioning

confidence: 99%

Second and third hepatectomies for recurrent hepatocellular carcinoma are justified

Cheng

Yeh

et al. 2009

British Journal of Surgery

View full text Add to dashboard Cite

show abstract

“…The Metastatic Lung Tumor Study Group in Japan reported that the number of pulmonary metastatic lesions is associated with prognosis, with good survival expected in cases with <4 metastatic lesions (23). Additionally, Chen et al (24) reported that patients with a metastasis of >3 cm had a worse prognosis compared to those with metastasis of <3 cm. In the present study, 2 patients in the non-treatment group underwent pulmonary resection; of those patients, 1 remains alive without recurrence, whereas the other patient survived for >3 years.…”

Section: Discussionmentioning

confidence: 99%

Combination therapy with S-1 and interferon-α in hepatocellular carcinoma patients with lung metastasis

Akita

Marubashi

Wada

et al. 2014

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. Managing extrahepatic recurrence in hepatocellular carcinoma (HCC) patients is crucial for improving prognosis. The present study aimed to investigate the effectiveness of using combination therapy with S-1 and interferon (IFN)-α in HCC patients with lung metastasis. Of the 646 patients who underwent radical surgery for HCC at our institute, 62 developed their first distant metastasis in the lung. Among these patients, 11 received S-1 combination therapy, while the remaining 51 patients received other conventional therapy, such as 5-fluorouracil and cisplatin or best supportive care. We retrospectively evaluated the toxicity and efficiency of combination therapy with S-1 and IFN-α. Hematological toxicity was observed in 5 patients and was grade 1 or 2 in all cases, except 1 patient (9.1%) who developed grade 3 leukopenia. Non-hematological toxicity was observed in 6 patients and was grade 1 in all cases, except 1 patient who exhibited a grade 2 increase of serum bilirubin levels. No patient required discontinuation of the S-1 combination therapy and no treatment-related mortality was reported during this study. Patients who received S-1 treatment exhibited significantly better survival after distant recurrence (SADR) compared to those without S-1 treatment (3-year survival rate, 81.8 vs. 43.1%, respectively; P=0.014). The multivariate analysis revealed that the S-1 treatment was prognostically significant for SADR (P= 0.0091; hazard ratio = 0.343). In conclusion, combination therapy with S-1 and IFN-α may be efficient for HCC patients with lung metastasis.

show abstract

“…Like many other studies in the past [6,7,8,10,11,12,13,14,16,17,18,19,20,21,22,23,24,25], only a limited number of patients was available for the study. To effectively use the limited number of patients, we conducted a survival analysis of these patients at the beginning and found a biphasic survival curve indicating that there were 2 groups of patients (Fig.…”

Section: Discussionmentioning

confidence: 99%

Clinical Factors Predicting Better Survival Outcome for Pulmonary Metastasectomy of Hepatocellular Carcinoma

et al. 2017

View full text Add to dashboard Cite

Background: In patients with lung metastasis of hepatocellular carcinoma (HCC), it remains uncertain how a better survival outcome can be predicted after metastasectomy. This study aims to identify clinical factors that may be used to guide patient selection for such a therapeutic modality. A total of 28 patients who received pulmonary metastasectomy for HCC between 1993 and 2012 were identified. All relevant clinical factors were extracted from medical records up to September 2015. Patients were classified into high- and low-risk groups according to survival outcome after metastasectomy. All pertinent clinical factors were analyzed for correlation with survival outcome. Summary: The overall survivalof 28 patients after pulmonary metastasectomy was studied first. The survival curve was biphasic and reached a plateau at 40 months after metastasectomy. The results indicate the presence of 2 groups of patients with a different survival outcome. Among all clinical parameters, remission status in the liver before pulmonary metastasectomy and distant metastasis-free interval between the last treatment of HCC and the occurrence of lung metastasis were found to be significantly associated with excellent survival outcome after pulmonary metastasectomy (p = 0.019 and 0.007 by Fisher exact test, and p = 0.002 and 0.0002 by Cox regression analysis).

show abstract

Pulmonary Resection for Metastases from Hepatocellular Carcinoma

Abstract: Pulmonary metastasectomy for hepatocellular carcinoma in selected patients was well justified when the maximum tumor size was <3 cm.

Cited by 38 publications

References 23 publications

Second and third hepatectomies for recurrent hepatocellular carcinoma are justified

Second and third hepatectomies for recurrent hepatocellular carcinoma are justified

Combination therapy with S-1 and interferon-α in hepatocellular carcinoma patients with lung metastasis

Clinical Factors Predicting Better Survival Outcome for Pulmonary Metastasectomy of Hepatocellular Carcinoma

Contact Info

Product

Resources

About